Patents Assigned to ALBUMEDIX LTD
  • Albumin variants and conjugates
    Patent number: 11555061
    Abstract: Based on the three-dimensional structure of albumin, the inventors have designed variant polypeptides (muteins) which have one or more cysteine residues with a free thiol group (hereinafter referred to as “thio-albumin”). The variant polypeptide may be conjugated through the sulphur atom of the cysteine residue to a conjugation partner such as a bioactive compound.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: January 17, 2023
    Assignee: ALBUMEDIX, LTD
    Inventors: Christopher John Arthur Finnis, Joanna Mary Hay, Esben Peter Friis, Jason Cameron, Darrell Sleep
  • Protein expression strains
    Patent number: 11130979
    Abstract: The invention provides an improved host strain for production of desired protein.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: September 28, 2021
    Assignee: Albumedix Ltd
    Inventors: Christopher John Arthur Finnis, Per Kristoffer Nordeide, Jennifer Mary McLaughlan
  • Albumin variants
    Patent number: 10934341
    Abstract: The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: March 2, 2021
    Assignee: ALBUMEDIX, LTD.
    Inventors: Jason Cameron, Karen Ann Delahay, Jens Erik Nielsen, Andrew Plumridge, Jan Terje Andersen
  • Albumin formulation and use
    Patent number: 10844349
    Abstract: The invention relates to a new formulation of albumin, a method for producing the albumin formulation and to uses of the albumin formulation, for example in cell culture such as mammalian cell culture and particularly in stem cell culture.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: November 24, 2020
    Assignee: Albumedix Ltd.
    Inventors: Sandra Marie Merkel, Luke Dimasi, Collette Ann Sheahan, Philip Harvey Morton
  • Variant serum albumin with improved half-life and other properties
    Patent number: 10711050
    Abstract: The invention provides methods and materials for making and using variant serum albumin amino acid sequences which exhibit improved properties compared to wild type serum albumin sequences. The invention further provides methods and materials for making and using fusion proteins in which the variant serum albumin amino acid sequences are fused to a therapeutic or diagnostic agent, such as a therapeutic protein, or a functional fragment or variant thereof that maintains activity, and exhibits improved properties.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: July 14, 2020
    Assignee: ALBUMEDIX LTD
    Inventors: Michael March Schmidt, Eric Steven Furfine, Amy Jada Andreucci, Thomas M. Barnes
  • Albumin variants
    Patent number: 10696732
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: June 30, 2020
    Assignee: ALBUMEDIX, LTD
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • PROTEIN EXPRESSION STRAINS
    Publication number: 20200157155
    Abstract: The invention provides an improved host strain for production of desired protein.
    Type: Application
    Filed: May 17, 2019
    Publication date: May 21, 2020
    Applicant: Albumedix LTD.
    Inventors: Christopher John Arthur Finnis, Jennifer Mary Mclaughlan, Per Kristoffer Nordeide, Preethi Ramaiya
  • Albumin variants and conjugates
    Patent number: 10633428
    Abstract: The present invention relates to conjugation-competent albumins and albumin-related polypeptides, and their conjugates with at least one moiety, and to polynucleotides encoding them.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: April 28, 2020
    Assignee: ALBUMEDIX LTD
    Inventors: Karen Ann Delahay, Christopher John Arthur Finnis, Karl Michael Nicholls
  • Albumin variants
    Patent number: 10501524
    Abstract: The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: December 10, 2019
    Assignee: ALBUMEDIX LTD
    Inventors: Jason Cameron, Karen Ann Delahay, Jens Erik Nielsen, Andrew Plumridge, Jan Terje Andersen
  • Albumin variants
    Patent number: 10329340
    Abstract: The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: June 25, 2019
    Assignee: ALBUMEDIX LTD
    Inventor: Karen Ann Delahay
  • Albumin derivatives and variants
    Patent number: 10233228
    Abstract: The application discloses albumin derivatives comprising or consisting of domain III and at least one further domain wherein the derivative or variant is not a naturally occurring albumin derivative or variant. The derivatives may be used in conjugates and fusion polypeptides.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: March 19, 2019
    Assignee: ALBUMEDIX LTD
    Inventors: Andrew Plumridge, Darrell Sleep, Inger Sandlie, Jan Terje Andersen, Jason Cameron, Leslie Evans, Steven Athwal, Elizabeth Allan, Esben Peter Friis